Dr. Reddy’s (RDY) Lauches Three New Generics in U.S.

Dr. Reddy’s Laboratories (NYSE: RDY) reports the launch of three new generics in the U.S. market.

The releasees:

• Donepezil Hydrochloride tablets (5mg and 10mg strengths), a bioequivalent generic version of ARICEPT tablets. The Food & Drug Administration (FDA) approved Dr. Reddy’s ANDA for Donepezil HCl tablets on May 31, 2011. Both strengths of Dr. Reddy’s Donepezil Hydrochloride tablets are available in 30, 90 and 500 count bottles.
  
  
• Venlafaxine Hydrochloride Extended Release capsules (37.5mg, 75mg and 150mg strengths), a bioequivalent generic version of EFFEXOR XR Extended Release capsules. The Food & Drug Administration (FDA) approved Dr. Reddy’s ANDA for Venlafaxine Hydrochloride Extended Release Capsules on May 05, 2011. All three strengths of Dr. Reddy’s Venlafaxine Hydrochloride Extended Release Capsules are available in 30, 90 and 500 count bottles.
  
  
• Letrozole tablets, USP (2.5mg), a bioequivalent generic version of FEMARA. The Food & Drug Administration (FDA) approved Dr. Reddy’s ANDA for Letrozole tablets, USP on June 3, 2011. Dr. Reddy’s Letrozole tablets, USP are available in 30 count bottles.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Getty Realty discloses separation terms for departing accounting officer
• Blue Moon Metals cleared to build at Nevada tungsten project
• Provident Financial prices $175M subordinated notes at 6.50%